---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-098035"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:05:07.340602+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics DKN-01 combo shows 11.3-month median PFS and 68% ORR in first-line gastric cancer at ESMO

## Summary
- Median PFS 11.3 months in overall first-line GEA patients in DisTinGuish study, exceeding benchmarks.
- ORR 68% overall, 90% in DKK1-high, 79% in PD-L1-low subgroups.
- Median OS not mature; 44% deceased as of June 30, 2022 cut; enrollment ongoing for randomized Part C.
- WAKING study (DKN-01 + atezolizumab) in 2nd/3rd-line OGA: 18 enrolled, DCR 50%, 1 PR; safety tolerable.
- Appointed Richard Schilsky, MD (former ASCO CMO) to Board effective Sept 1, 2022.

## SEC filing metadata
- accession: 0001104659-22-098035
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/tm2225135d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-098035
- JSON: https://secwatch.observer/filing/0001104659-22-098035.json
- Plain text: https://secwatch.observer/filing/0001104659-22-098035.txt

## Key facts
- Executive change
  Richard Schilsky was appointed as Class I director at CYPHERPUNK TECHNOLOGIES INC..
  - Action: appointed
  - Role: Class I director
  source text: On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.